Autor: |
Fang AM; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Hayek O; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Kaylor JM; Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Peyton CC; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA., Ferguson JE 3rd; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA., Nix JW; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA., Rais-Bahrami S; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.; Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. |
Abstrakt: |
Objective: To compare outcomes in patients undergoing robotic-assisted radical cystectomy (RARC) with urinary diversion for bladder cancer with either the single-port (SP) or multiport (MP) robotic platform. Methods: All patients who underwent SP and MP RARC at our institution between January 2018 and January 2023 were retrospectively reviewed. Postoperative analgesia was administered by a departmentwide narcotic stewardship protocol, and inpatient and outpatient narcotic use was tracked. The available preoperative clinical, operative, and postoperative outcomes were analyzed using t -test, chi-square, and Fischer exact statistical measures. Kaplan-Meier analysis with log-rank testing was used to determine the freedom from high-grade (Clavien-Dindo grade ≥3) postoperative complications stratified by SP or MP robotic use. Results: Overall, 96 patients underwent RARC with urinary diversion at our institution, with 49 MP and 47 SP procedures performed. Preoperative clinical parameters including age, body mass index, prior abdominal surgery, and use of neoadjuvant chemotherapy were similar between the two groups. Patients undergoing SP RARC had a shorter operative time (386.0 ± 90.9 minutes vs 453.6 ± 94.8 minutes, p < 0.01) and faster return of bowel function (3.4 ± 1.4 days vs 4.5 ± 2.2 days, p < 0.01). However, both cohorts had similar length of hospitalization, postoperative narcotic use, pathologic staging, and rate of positive surgical margin. Within 3 months postoperatively, both cohorts had a similar high-grade complication, hospital readmission, and cancer recurrence rate. Conclusions: The SP robot allows a safe alternative surgical approach for RARC and offers similar postoperative outcomes compared to the MP robot. |